e20567Background: Advances in cancer diagnostics including genomic testing has improved our ability to determine the likely tissue of origin (TOO) in CUP. We aimed to describe the clinical and ...

PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

The cyclin-dependent kinase 4/6 (CDK4/6) inhibitors palbociclib, abemaciclib, and ribociclib each showed a significant or strong trend to improve overall survival (OS) when given as second-line ...

PURPOSEPharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration–approved for ...

Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization Project ...

PURPOSETo our knowledge, the ACHILLES/TORG1834 trial is the first randomized study comparing afatinib and chemotherapy in patients with non–small cell lung cancer (NSCLC) harboring sensitizing ...

At 12-year follow-up, C9741 confirmed the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer. SET2,3 identified patients with ER+ breast cancer who ...

Under-reporting of treatment-related adverse events is commonplace in cancer drug trials, which are often accompanied by terms that downplay the seriousness of these events. 1 - 3 Cardiovascular ...

PURPOSEFatigue is a highly prevalent and disabling symptom for patients with metastatic breast cancer (MBC). Evidence-based interventions for managing fatigue in advanced cancer populations are ...

PURPOSEArtificial intelligence (AI) tools that identify pathologic features from digitized whole-slide images (WSIs) of prostate cancer (CaP) generate data to predict outcomes. The objective of this ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

A phase 1b dose escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer.